The 2023 European Society of Hypertension (ESH) and 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines both emphasize proper blood pressure (BP) ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

Patients with heart failure (HF) who had an interatrial shunt inserted did not see any significant benefits overall, compared with those who underwent a placebo procedure, after a median 22-month ...

In this week’s View, Dr. Eagle looks at the new ACC/AHA guideline for prevention, detection, evaluation and management of high blood pressure (BP). He then discusses new-onset right bundle branch ...

The 2025 ACC/AHA Acute Coronary Syndrome (ACS) Guideline clarifies diagnostic distinctions using electrocardiogram changes, troponin levels, and imaging tools such as coronary CT angiography and ...

The U.S. Food and Drug Administration (FDA) has approved finerenone to treat patients with heart failure (HF) with LVEF ≥40%. The approval was based on results from the FINEARTS-HF trial, presented at ...

The ACC has issued guidance for the diagnosis and management of acute myocarditis in adult patients, delivering a streamlined decision-making framework that reflects recent advancements in clinical ...

Asundexian was associated with a higher incidence of stroke or systemic embolism, but less major bleeding, compared with apixaban among patients with atrial fibrillation (AFib) who were at high risk ...

In patients with pre-existing cardiovascular disease and who are overweight or obese, but who do not have diabetes, 2.4 mg of subcutaneous semaglutide taken once weekly was superior to placebo in ...

Alpha-Gal Syndrome (AGS) is an underrecognized, tick-borne allergic condition with emerging relevance in cardiovascular medicine. Sensitization to galactose-α-1,3-galactose (alpha-gal), a ...

Psychological stress and mental health concerns are both risk factors for and possible complications of cardiovascular disease (CVD). These connections have been recognized in publications dating back ...

Global death counts due to cardiovascular disease (CVD) increased from 12.4 million in 1990 to 19.8 million in 2022, reflecting global population growth and aging and the contributions from ...